跳至主要内容
临床试验/NCT05330312
NCT05330312已完成不适用

A Randomized, Controlled, Parallel-group Clinical Investigation Evaluating the Impact of Digital Cognitive Behavioural Therapy on Psychological Symptom Burden in Adults Diagnosed With Pulmonary Fibrosis

Vicore Pharma AB2 个研究点 分布在 1 个国家目标入组 119 人开始时间: 2022年4月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
119
试验地点
2
主要终点
Part 1 - Subject Feedback on Functionality and Experience of the dCBT-PF at Week 4

研究概览

简要总结

The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.

详细描述

Patients will be randomised 1:1 to either receive treatment with the digital therapy, or to act as control group. Patients will be treated for 9 weeks, followed by a 3 week follow-up period. Efficacy will be assessed after 9 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

HAM-A raters are blinded (HAM-A = Hamilton Anxiety Rating Scale).

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥22 years at the time of signing the informed consent
  • •Self-reported Pulmonary Fibrosis diagnosis
  • •A GAD-7 score of ≥5 at pre-screening and baseline
  • •If currently on prescribed medication for depression/anxiety, a stable dose for at least 4 weeks prior to baseline
  • •CT scan report within 5 years prior to baseline with signs of PF (interstitial changes)
  • •Capable of using a mobile device and common applications, and has an appropriate mobile or tablet device

排除标准

  • •Self-reported manic disorders, psychotic disorders, schizophrenia, or alcohol/drug abuse during the past 6 months prior to baseline (Visit 1), as judged by the investigator or designee.
  • •Self-reported history of hospital admissions due to suicidal behavior or attempts, as judged by the investigator or designee
  • •Self-reported previous or current diagnosis of major depressive disorder, as judged by the investigator or designee
  • •Verbal and/or written communication problems limiting ability to engage with dCBT-IPF
  • •Inability to comply with investigation procedures, due to e.g. cognitive impairment or severe medical conditions as judged by the investigator or designee
  • •Currently receiving cognitive behavioral therapy

研究组 & 干预措施

Part 2 - Control group

No Intervention

No intervention

Part 2 - Digital cognitive behavioral therapy

Experimental

9 weeks digital cognitive behavioral therapy

干预措施: Digital cognitive behavioral therapy (Device)

Part 1 - Digital cognitive behavioral therapy

Experimental

4 weeks digital cognitive behavioral therapy.

干预措施: Digital cognitive behavioral therapy (Device)

结局指标

主要结局

Part 1 - Subject Feedback on Functionality and Experience of the dCBT-PF at Week 4

时间窗: Baseline to Week 4

Subject feedback on functionality and experience of the dCBT-PF at Week 4 collected through subject interviews following a separate semi-structured interview guide.

Part 2 - Change From Baseline in Anxiety Symptom Severity Assessed by Generalized Anxiety Disorder 7-item (GAD-7) at Week 9.

时间窗: Baseline to Week 9

The questionnaire includes 7 questions. Each question will be scored on a 4-point scale from 0 to 3 points. Higher score will mean a worse outcome. The GAD-7 represents an anxiety measure based on seven items which are scored from zero to three (0=Not at all,1=Several days, 2=More than half the days and 3=Nearly every day). The composite score can range from 0 to 21 and cut-off scores for mild, moderate and severe anxiety symptoms are 5, 10 and 15 respectively.

次要结局

  • Part 2- Change From Baseline in HRQoL Assessed by King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 9.(Baseline to Week 9)
  • Part 1 - Safety of dCBT-PF-in Patients With IPF(Baseline to week 4)
  • Part 2 - Change From Baseline in Anxiety Symptom Severity as Assessed by Hamilton Anxiety Rating Scale (HAM-A) at Week 9(Baseline to Week 9)
  • Part 2 - Change From Baseline in HRQoL Assessed by King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Psychological Domain Score at Week 9.(Baseline to Week 9)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验